MGNX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MG

Mkt Cap

$206.7M

Volume

347.33K

Next Earnings

November 11th

Loading chart

MG

MGNXMacroGenics, Inc.

MGNX

Pay with—

Available Balance0.00

MG

Mkt Cap

$214.7M

Volume

347.33K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?MacroGenics (MGNX) and C4 Therapeutics (CCCC) are outperforming the broader Medical sector year-to-date. MGNX has returned 120.5% compared to a -0.4% average for Medical stocks, with analyst consensus estimates for full-year earnings up 50.6% over the past three months. CCCC has returned 49.2% with a 1.7% increase in consensus EPS estimates. Both stocks hold Zacks Rank #2 (Buy) ratings.Zacks Investment Research · Oct 9, 2026

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsightThe chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.GlobeNewswire Inc. · Sep 8, 2026

MacroGenics to Participate in Upcoming Investor ConferencesMacroGenics, Inc. announced that its management team, led by President and CEO Eric Risser, will participate in four major investor conferences in March 2026, including TD Cowen, Leerink Partners, Citizens, and Barclays healthcare conferences. The company will conduct presentations, fireside chats, and one-on-one meetings with investors. Webcasts of the presentations will be available on the company's investor relations website.GlobeNewswire Inc. · Feb 26, 2026

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET TrialThe FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab, a bispecific antibody targeting PD-1 and CTLA-4 for gynecologic cancers. The hold follows safety events in four patients including Grade 4 thrombocytopenia, myocarditis, neutropenia with septic shock, and one death. No new patients will be enrolled until the hold is lifted, though current participants may continue treatment.GlobeNewswire Inc. · Feb 23, 2026

[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expansion initiatives across North America, Europe, and Asia-Pacific regions.GlobeNewswire Inc. · Jan 14, 2026

MacroGenics Revenue Doubles in Q2MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.The Motley Fool · Aug 14, 2025

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More InformationJohnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.GlobeNewswire Inc. · Feb 6, 2025

Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth PotentialThe global immunotoxins market is projected to grow at a CAGR of 8.11% from 2024 to 2034, driven by the rising prevalence of malignancies, increased R&D, and the approval of new immunotoxin therapies. Diphtheria toxin-based immunotoxins lead revenue, while Pseudomonas exotoxins show rapid growth potential.GlobeNewswire Inc. · Jan 9, 2025

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More InformationJohnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.GlobeNewswire Inc. · Oct 23, 2024

Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsightThe market for B7-H3 inhibitors is expected to grow significantly due to rising investment from leading pharma companies, increasing cancer diagnoses, and a growing number of B7-H3 inhibitors in clinical trials.GlobeNewswire Inc. · Oct 7, 2024

to start trading

MG

MGNXMacroGenics, Inc.

MGNX

Pay with—

Available Balance0.00

Your PositionYou don't own any MGNX yet.

Related Tickers

Earnings